New targets for inhibitors of HIV-1 replication

被引：128

作者：

Moore, JP

Stevenson, M

机构：

[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA

[2] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA

[3] Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA

来源：

NATURE REVIEWS MOLECULAR CELL BIOLOGY | 2000年 / 1卷 / 01期

关键词：

D O I：

10.1038/35036060

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Despite the success of protease and reverse transcriptase inhibitors, new drugs to suppress HIV-1 replication are still needed. Several other early events in the viral life cycle (stages before the viral genome is inserted into host cell DNA) are susceptible to drugs, including virus attachment to target cells, membrane fusion and post-entry events such as integration, accessory-gene function and assembly of viral particles. Among these, inhibitors of virus-cell fusion and integration are the most promising candidates.

引用

收藏

页码：40 / 49

页数：10

相关论文

共 104 条

[1] HIV coreceptor downregulation as antiviral principle: SDF-1 alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication [J].

Amara, A ;

LeGall, S ;

Schwartz, O ;

Salamero, J ;

Montes, M ;

Loetscher, P ;

Baggiolini, M ;

Virelizier, JL ;

ArenzanaSeisdedos, F .

JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :139-146

[2] T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure [J].

Arakaki, R ;

Tamamura, H ;

Premanathan, M ;

Kanbara, K ;

Ramanan, S ;

Mochizuki, K ;

Baba, M ;

Fujii, N ;

Nakashima, H .

JOURNAL OF VIROLOGY, 1999, 73 (02) :1719-1723

[3] A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].

Baba, M ;

Nishimura, O ;

Kanzaki, N ;

Okamoto, M ;

Sawada, H ;

Iizawa, Y ;

Shiraishi, M ;

Aramaki, Y ;

Okonogi, K ;

Ogawa, Y ;

Meguro, K ;

Fujino, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703

[4] A new classification for HIV-1 [J].

Berger, EA ;

Doms, RW ;

Fenyö, EM ;

Korber, BTM ;

Littman, DR ;

Moore, JP ;

Sattentau, QJ ;

Schuitemaker, H ;

Sodroski, J ;

Weiss, RA .

NATURE, 1998, 391 (6664) :240-240

[5]

BERGER EA, 1997, AIDS, V11, P3

[6] Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication [J].

Berthoux, L ;

Péchoux, C ;

Darlix, JL .

JOURNAL OF VIROLOGY, 1999, 73 (12) :10000-10009

[7] In vivo HIV-1 infection of CD45RA+CD4+ T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ T cell decline [J].

Blaak, H ;

van't Wout, AB ;

Brouwer, M ;

Hooibrink, B ;

Hovenkamp, E ;

Schuitemaker, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (03) :1269-1274

[8] The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry [J].

Bleul, CC ;

Farzan, M ;

Choe, H ;

Parolin, C ;

ClarkLewis, I ;

Sodroski, J ;

Springer, TA .

NATURE, 1996, 382 (6594) :829-833

[9] Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A [J].

Braaten, D ;

Aberham, C ;

Franke, EK ;

Yin, L ;

Phares, W ;

Luban, J .

JOURNAL OF VIROLOGY, 1996, 70 (08) :5170-5176

[10]

BUGELSKI PJ, 1991, J ACQ IMMUN DEF SYND, V4, P923

← 1 2 3 4 5 6 7 8 9 10 →